RELENZA helps stop viral replication and may shorten the duration of influenza A and B symptoms. Learn more.

RELENZA helps to prevent influenza infection. Learn more.

Important Safety Information RELENZA is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease). Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airways disease. Many of these cases were reported during postmarketing and causality was difficult to assess. If use of RELENZA is considered for a patient with underlying airways disease, the potential risks and benefits should be carefully weighed. Use in these patients should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators. Discontinue RELENZA and initiate appropriate treatment if an allergic reaction occurs or is suspected. Patients with influenza, particularly pediatric patients, may be at an increased risk of seizures, confusion, or abnormal behavior early in their illness. Monitor for signs of abnormal behavior. Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions. RELENZA has not been proven effective for prophylaxis of influenza in the nursing home setting. RELENZA is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control’s Immunization Practices Advisory Committee. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish the clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA. Click here for Complete Prescribing Information for RELENZA.

*Clinical significance cannot be inferred from surveillance data.